CY1126034T1 - Παραγωγα διυδροχρωμενιου - Google Patents

Παραγωγα διυδροχρωμενιου

Info

Publication number
CY1126034T1
CY1126034T1 CY20231100250T CY231100250T CY1126034T1 CY 1126034 T1 CY1126034 T1 CY 1126034T1 CY 20231100250 T CY20231100250 T CY 20231100250T CY 231100250 T CY231100250 T CY 231100250T CY 1126034 T1 CY1126034 T1 CY 1126034T1
Authority
CY
Cyprus
Prior art keywords
hydrogen atom
hydrochromium
derivatives
tumor
recurrence
Prior art date
Application number
CY20231100250T
Other languages
Greek (el)
English (en)
Inventor
Hitoshi Ban
Seiji Kamioka
Yusuke SAWAYAMA
Miki HASHIZUME
Original Assignee
Sumitomo Pharma Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma Co., Ltd. filed Critical Sumitomo Pharma Co., Ltd.
Publication of CY1126034T1 publication Critical patent/CY1126034T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
CY20231100250T 2018-03-20 2023-05-26 Παραγωγα διυδροχρωμενιου CY1126034T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018052971 2018-03-20
PCT/JP2019/011439 WO2019181939A1 (ja) 2018-03-20 2019-03-19 ジヒドロクロメン誘導体

Publications (1)

Publication Number Publication Date
CY1126034T1 true CY1126034T1 (el) 2023-11-15

Family

ID=67986459

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20231100250T CY1126034T1 (el) 2018-03-20 2023-05-26 Παραγωγα διυδροχρωμενιου

Country Status (21)

Country Link
US (3) US10807993B2 (https=)
EP (1) EP3770162B1 (https=)
JP (4) JP6733072B2 (https=)
KR (1) KR102799186B1 (https=)
CN (1) CN111886237B (https=)
AU (1) AU2019239481B2 (https=)
CA (1) CA3092255A1 (https=)
CY (1) CY1126034T1 (https=)
DK (1) DK3770162T3 (https=)
EA (1) EA202092206A1 (https=)
ES (1) ES2941771T3 (https=)
FI (1) FI3770162T3 (https=)
HU (1) HUE062256T2 (https=)
MX (1) MX2020009763A (https=)
MY (1) MY202583A (https=)
PH (1) PH12020551497A1 (https=)
PL (1) PL3770162T3 (https=)
PT (1) PT3770162T (https=)
SG (1) SG11202007979UA (https=)
TW (1) TWI899051B (https=)
WO (1) WO2019181939A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3770162T3 (pl) * 2018-03-20 2023-06-05 Sumitomo Pharma Co., Ltd. Pochodne dihydrochromenu
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
WO2025100519A1 (ja) * 2023-11-09 2025-05-15 住友ファーマ株式会社 ジヒドロクロメン誘導体を含むがんの治療剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045707A1 (en) 1999-12-21 2001-06-28 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US20090111805A1 (en) 2005-02-24 2009-04-30 Pfizer Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
US20080255149A1 (en) * 2005-09-27 2008-10-16 Novartis Ag Carboxyamine Compounds and Methods of Use Thereof
EP1847542A1 (en) 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
HRP20160625T1 (hr) * 2007-09-10 2016-08-12 Boston Biomedical, Inc. Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
RU2018101897A (ru) * 2015-06-22 2019-07-24 Сумитомо Дайниппон Фарма Ко., Лтд. Бициклическое гетероциклическое амидное производное
CA2990583A1 (en) 2015-06-22 2016-12-29 Sumitomo Dainippon Pharma Co., Ltd. 1,4-disubstituted imidazole derivative
JP6896701B2 (ja) * 2016-02-26 2021-06-30 大日本住友製薬株式会社 イミダゾリルアミド誘導体
TW201821105A (zh) * 2016-10-20 2018-06-16 美商弗瑪治療公司 使用hdac11抑制劑之方法
PL3770162T3 (pl) 2018-03-20 2023-06-05 Sumitomo Pharma Co., Ltd. Pochodne dihydrochromenu
JP2020019752A (ja) 2018-08-03 2020-02-06 大日本住友製薬株式会社 クロマン誘導体

Also Published As

Publication number Publication date
KR102799186B1 (ko) 2025-04-23
CN111886237A (zh) 2020-11-03
US20230219970A1 (en) 2023-07-13
JP6733072B2 (ja) 2020-07-29
US20200216461A1 (en) 2020-07-09
MX2020009763A (es) 2020-10-08
JP2024123117A (ja) 2024-09-10
FI3770162T3 (fi) 2023-06-02
AU2019239481A1 (en) 2020-09-10
KR20200135401A (ko) 2020-12-02
CA3092255A1 (en) 2019-09-26
US20210002290A1 (en) 2021-01-07
EP3770162B1 (en) 2023-03-15
BR112020017481A8 (pt) 2022-12-06
JPWO2019181939A1 (ja) 2020-06-18
SG11202007979UA (en) 2020-09-29
US10807993B2 (en) 2020-10-20
DK3770162T3 (da) 2023-04-24
EP3770162A4 (en) 2021-12-01
US11639357B2 (en) 2023-05-02
EP3770162A1 (en) 2021-01-27
PL3770162T3 (pl) 2023-06-05
HUE062256T2 (hu) 2023-10-28
MY202583A (en) 2024-05-09
US12398149B2 (en) 2025-08-26
CN111886237B (zh) 2025-02-07
JP7508620B2 (ja) 2024-07-01
ES2941771T3 (es) 2023-05-25
EA202092206A1 (ru) 2020-12-15
JP2023075288A (ja) 2023-05-30
NZ767234A (en) 2025-06-27
JP2020180140A (ja) 2020-11-05
AU2019239481B2 (en) 2022-11-24
BR112020017481A2 (pt) 2020-12-22
PT3770162T (pt) 2023-03-23
JP7247144B2 (ja) 2023-03-28
TWI899051B (zh) 2025-10-01
PH12020551497A1 (en) 2021-09-01
WO2019181939A1 (ja) 2019-09-26
TW201941774A (zh) 2019-11-01

Similar Documents

Publication Publication Date Title
CY1126034T1 (el) Παραγωγα διυδροχρωμενιου
CY1126066T1 (el) Υποκατεστημενα παραγωγα θειενο[2,3-d]πυριμιδινης ως αναστολεις της μενινης-mll και μεθοδοι χρησης
CY1123991T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1125279T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1119901T1 (el) Αναστολεις απομεθυλασων ιστονων
CY1123177T1 (el) Ρυθμιστης υποδοχεα ανδρογονου και χρησεις αυτου σε συνδυασμο με οξεικη αμπιρατερονη και πρεδνιζονη για τη θεραπεια καρκινου του προστατη
CY1124514T1 (el) Ενωσεις [1,2,4]τριαζολο[1,5-α]πυριδινυλ-υποκατεστημενης ινδολης
CY1118874T1 (el) Ανθρωποποιημενα αντισωματα εναντια στη liv-1 και χρηση αυτων για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1119844T1 (el) 1η-πυραζολο[3,4-β]πυριδινες και θεραπευτικες χρησεις αυτων
CY1122983T1 (el) Νεες ενωσεις
MX2020008754A (es) Compuestos farmaceuticos.
CY1124952T1 (el) Αλατα παραγωγων πυρρολοτριαζινης χρησιμα ως αναστολεις ταμ
CY1122945T1 (el) Αναλογα διοξολανιου της ουριδινη για τη θεραπεια του καρκινου
CY1124814T1 (el) Συμπυκνωμενα παραγωγα ιμιδαζολιου υποκατεστημενα με τριτοταγεις υδροξυ ομαδες ως αναστολεις ρi3κ-γαμμα
CY1117719T1 (el) Παραγωγα αμινοπυριμιδινης ως διαμορφωτες της lrrk2
CY1119084T1 (el) Υποκατεστημενα τρικυκλικα βενζιμιδαζολια ως αναστολεις κινασης
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
CY1117712T1 (el) Adcs δουοκαρμυκινης για χρηση στη θεραπεια ενδομητριου καρκινου
MX390630B (es) Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
CY1122613T1 (el) Παραγωγα 4-οξο-3,4-διυδρο-1,2,3-βενζοτριαζινης ως ρυθμιστες toy gpr139
CY1119473T1 (el) 1-υδροξυ-βενζοοξαβορολια ως αντιπαρασιτικοι παραγοντες
CY1116192T1 (el) Πυρρολοβενζοδιαζεπινες και συζευγματα αυτων
CY1122182T1 (el) Ανοσοκατασταλτικες φαρμακοτεχνικες μορφες
CY1110962T1 (el) Τρικυκλικες ενωσεις και η χρηση τους ως διαμορφωτες του υποδοχεα γλυκοκορτικοειδων
CY1119425T1 (el) Ενωσεις φαινοξυαιθυλο πιπεριδινης